Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2

Conditions

Pain 23Neoplasms 19Cancer Pain 9Colonic Neoplasms 7Breakthrough Pain 7Agnosia 7Breast Neoplasms 5Rectal Neoplasms 4Prostatic Neoplasms 4Lung Neoplasms 4Head and Neck Neoplasms 4Chronic Pain 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Pain, Postoperative 3Sarcoma 2Pleural Effusion, Malignant 2Lymphoma, Follicular 2Diverticulosis, Colonic 2Carcinoma, Hepatocellular 2Burns 2Brain Neoplasms 2Anemia, Sickle Cell 2post laminectomy syndrome 1Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vipoma 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1

Interventions

Fentanyl 2Sugars 1Fenofibrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Burns × Fentanyl × Clear all
NCT00236041 2014-05-09

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
38 enrolled
Classical hematology

Agnosia, Anemia, Sickle Cell, Burns, Neoplasms, Breakthrough Pain

NCT00236093 2014-05-09

Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
Classical hematology

Anemia, Sickle Cell, Burns, Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡